Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids

Simple item page
dc.contributor.authorSarmiento, Mauricio
dc.contributor.authorRojas, Patricio
dc.contributor.authorJerez, Joaquin
dc.contributor.authorBertin, Pablo
dc.contributor.authorCampbell, James
dc.contributor.authorGarcia, Maria J.
dc.contributor.authorPereira, Jaime
dc.contributor.authorTriantafilo, Nicolas
dc.contributor.authorOcqueteau, Mauricio
dc.date.accessioned2025-01-20T22:19:04Z
dc.date.available2025-01-20T22:19:04Z
dc.date.issued2021
dc.description.abstractIntroduction: Currently, severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is a major public health problem worldwide. Although most patients present a mild infection, effective strategies are required for patients who develop the severe disease. Anti-inflammatory treatment with JAK inhibitors has been considered in SARS-CoV-2. Methods: In this study, we presented our experience in a group of severe SARS-CoV-2 Chilean patients. This prospective study was performed on consecutive patients presenting severe respiratory failure owing to COVID-19 or high-risk clinical condition associated with SARS-CoV-2, and who were treated with ruxolitinib for management of associated inflammation. Overall, 18 patients presenting SARS-CoV-2 viral-induced hyperinflammation were treated with ruxolitinib, with 16 patients previously treated with steroids, 4 with tocilizumab, and 3 with both treatments. Results: Ten patients evolved with favorable response, including 7 patients admitted with severe respiratory failure (PaFi less than 200 mm Hg in high-flow nasal cannula), presenting complete regression of hyperinflammation, regression of the lung lesions, and subsequent discharge. In the remaining 8 patients, 25% showed reduced inflammation, but early discharge was not achieved owing to the slow evolution of respiratory failure. Unfortunately, 3 patients demonstrated a severe respiratory failure. The early initiation of ruxolitinib was found to be associated with better clinical evolution (p < 0.005). Conclusion: In this study, ruxolitinib resolved hyperinflammatory state in 55% of the patients, regardless of the previous steroid or tocilizumab therapy. Unfortunately, few patients demonstrated severe evolution despite ruxolitinib therapy. Notably, the treatment starting time appears to play an important role in achieving good outcomes. Further validation in randomized controlled trials is crucial.
dc.fuente.origenWOS
dc.identifier.doi10.1159/000516464
dc.identifier.eissn1421-9662
dc.identifier.issn0001-5792
dc.identifier.urihttps://doi.org/10.1159/000516464
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94586
dc.identifier.wosidWOS:000662283800001
dc.issue.numero6
dc.language.isoen
dc.pagina.final626
dc.pagina.inicio620
dc.revistaActa haematologica
dc.rightsacceso restringido
dc.subjectCoronavirus disease-19
dc.subjectRuxolitinib
dc.subjectJanus kinase
dc.subjectsignal transducer and activator of transcription
dc.subjectInflammation
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleRuxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids
dc.typeartículo
dc.volumen144
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas